- Home
- LII vs MRNA Comparison
LII vs MRNA Comparison
Compare LII & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LII
- MRNA
- Stock Information
- Founded
- LII 1895
- MRNA 2010
- Country
- LII United States
- MRNA United States
- Employees
- LII N/A
- MRNA N/A
- Industry
- LII Industrial Machinery/Components
- MRNA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LII Industrials
- MRNA Health Care
- Exchange
- LII Nasdaq
- MRNA Nasdaq
- Market Cap
- LII 19.8B
- MRNA 16.0B
- IPO Year
- LII 1999
- MRNA 2018
- Fundamental
- Price
- LII $556.15
- MRNA $24.72
- Analyst Decision
- LII Hold
- MRNA Hold
- Analyst Count
- LII 11
- MRNA 20
- Target Price
- LII $621.00
- MRNA $54.47
- AVG Volume (30 Days)
- LII 447.0K
- MRNA 10.2M
- Earning Date
- LII 04-23-2025
- MRNA 05-01-2025
- Dividend Yield
- LII 0.82%
- MRNA N/A
- EPS Growth
- LII 36.28
- MRNA N/A
- EPS
- LII 22.54
- MRNA N/A
- Revenue
- LII $5,341,300,000.00
- MRNA $3,236,000,000.00
- Revenue This Year
- LII $3.06
- MRNA N/A
- Revenue Next Year
- LII $6.39
- MRNA $22.07
- P/E Ratio
- LII $24.67
- MRNA N/A
- Revenue Growth
- LII 7.21
- MRNA N/A
- 52 Week Low
- LII $445.63
- MRNA $23.15
- 52 Week High
- LII $682.50
- MRNA $170.47
- Technical
- Relative Strength Index (RSI)
- LII 47.68
- MRNA 36.68
- Support Level
- LII $540.89
- MRNA $23.68
- Resistance Level
- LII $566.92
- MRNA $27.21
- Average True Range (ATR)
- LII 27.42
- MRNA 2.06
- MACD
- LII 2.24
- MRNA -0.03
- Stochastic Oscillator
- LII 70.41
- MRNA 26.98
About LII Lennox International Inc.
Lennox International manufactures and distributes heating, ventilating, air conditioning, and refrigeration products to replacement (75% of sales) and new construction (25% of sales) markets. In fiscal 2024, residential HVAC was 67% of sales and commercial HVAC and Heatcraft refrigeration was 33% of sales. The company goes to market with multiple brands, but Lennox is the company's flagship HVAC brand. The Texas-based company is focused on North America after the sale of its European HVAC and refrigeration businesses in late 2023.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.